Ghent University Academic Bibliography

Advanced

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (vol 377, pg 42, 2011)

Gilles Salles, John Francis Seymour and Fritz Offner UGent (2011) LANCET. 377(9772). p.1154-1154
Please use this url to cite or link to this publication:
author
organization
year
type
misc (correction)
publication status
published
subject
in
LANCET
Lancet
volume
377
issue
9772
pages
1154 - 1154
Web of Science type
Correction
Web of Science id
000289539300028
JCR category
MEDICINE, GENERAL & INTERNAL
JCR impact factor
38.278 (2011)
JCR rank
2/153 (2011)
JCR quartile
1 (2011)
ISSN
0140-6736
language
English
UGent publication?
yes
classification
V
id
2005648
handle
http://hdl.handle.net/1854/LU-2005648
date created
2012-01-27 10:20:38
date last changed
2016-12-19 15:47:49
@misc{2005648,
  author       = {Salles, Gilles and Seymour, John Francis and Offner, Fritz},
  issn         = {0140-6736},
  language     = {eng},
  number       = {9772},
  pages        = {1154--1154},
  series       = {LANCET},
  title        = {Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (vol 377, pg 42, 2011)},
  volume       = {377},
  year         = {2011},
}

Chicago
Salles, Gilles, John Francis Seymour, and Fritz Offner. 2011. “Rituximab Maintenance for 2 Years in Patients with High Tumour Burden Follicular Lymphoma Responding to Rituximab Plus Chemotherapy (PRIMA): a Phase 3, Randomised Controlled Trial (vol 377, Pg 42, 2011).” Lancet.
APA
Salles, Gilles, Seymour, J. F., & Offner, F. (2011). Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (vol 377, pg 42, 2011). LANCET.
Vancouver
1.
Salles G, Seymour JF, Offner F. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (vol 377, pg 42, 2011). LANCET. 2011. p. 1154–1154.
MLA
Salles, Gilles, John Francis Seymour, and Fritz Offner. “Rituximab Maintenance for 2 Years in Patients with High Tumour Burden Follicular Lymphoma Responding to Rituximab Plus Chemotherapy (PRIMA): a Phase 3, Randomised Controlled Trial (vol 377, Pg 42, 2011).” LANCET 2011 : 1154–1154. Print.